Trio of genes plays role in breast ca mets to brain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Cell surface coating may play a major role in the spread of breast cancer to the brain, according to a study out of Memorial Sloan-Kettering Cancer Center in New York. Three genes-COX2, HB-EGF, and ST6GALNAC5-have been found to mediate the metastasis of breast cancer to the brain, reported lead author Joan Massagué, PhD, and colleagues (Nature online, May 6, 2009)

Cell surface coating may play a major role in the spread of breast cancer to the brain, according to a study out of Memorial Sloan-Kettering Cancer Center in New York. Three genes-COX2, HB-EGF, and ST6GALNAC5-have been found to mediate the metastasis of breast cancer to the brain, reported lead author Joan Massagu, PhD, and colleagues (Nature online, May 6, 2009).

COX2 and HB-EGF induce cancer cell mobility and invasiveness, while ST6GALNAC5 provide cells with the capability of exiting the blood circulation and passing through the blood-brain barrier, they explained. The researchers isolated cancer cells that preferentially targeted the brain from patients with advanced disease.

Articles in this issue
Letrozole appears less detrimental than tamoxifen to cognitive function in breast ca
Accelerated whole-breast irradiation does more with less after lumpectomy
RIBBON-1 results bolster bevacizumab as add-on to standard Rx for metastatic breast cancer
PET/CT Indicates if Early Neoadjuvant Rx is Making the Grade in Sarcoma Patients
Less is more when it comes to serial CA125 testing in ovarian cancer
Treatment varies widely in chronic myeloid leukemia
Should expectant management serve as the primary treatment option in prostate cancer?
Oncology takes blame for rising healthcare cost
Healthcare advocates call for universal coverage, acknowledge challenges
NSABP chair admits ‘failure’ in C-08 trial, denies defeat
Gemcitabine, capecitabine regimens equal in breast ca mets
Study ties survival to inflammatory markers in breast cancer
Canadians rally for national standards for breast ca testing
Trio of genes plays role in breast ca mets to brain
Micromet BiTE antibody eliminates leukemia cells
Recent Videos
Regardless of disease burden or disease progression speed on front-line therapy, trastuzumab deruxtecan appears effective in HER2-low breast cancer.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Related Content
Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer

Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer

Ariana Pelosci
February 14th 2025
Article

Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer

Roman Fabbricatore
February 12th 2025
Article

Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations

Rachel A. Greenup, MD, MPH
December 23rd 2024
Podcast

A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

Managing Brain Metastases in Patients with HER2+ Metastatic Breast Cancer

ONCOLOGY Staff
February 9th 2025
Article

The panel discussed the different ways to treat patients with HER2-positive metastatic breast cancer who also have brain metastases.

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.

Hormone Therapy Confers Modest Breast Cancer Risk Even With Family History

Russ Conroy
February 8th 2025
Article

Risk model data may provide reassurance for individuals undergoing hormone therapy with an already heightened breast cancer risk due to family history.